Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR
Range Of New Modalities Put To Test
Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.
You may also be interested in...
Moderna’s Bancel Dismisses GSK And Sanofi Challenge In mRNA Vaccines
Under pressure to show Moderna can grow the company’s mRNA vaccines portfolio beyond COVID-19, CEO Stéphane Bancel has talked down his rivals in the field.
Affimed’s AFM13 Data Show Potential Of NK Cell Approach
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.